
    
      Efficacy of Doryx Delayed Release Tablets to doxycycline hyclate will be assessed using an
      Investigator's Global Assessment (IGA) score and the absolute change from baseline to 12
      weeks in inflammatory lesion count in patients with moderate to severe facial acne vulgaris.
      Additionally, the absolute change from baseline to 12 weeks in non-inflammatory lesions count
      of Doryx Delayed Release Tablets compared to doxycycline hyclate will be evaluated.
    
  